hemophilia
| 2 min read
Qfitlia, an RNAi therapeutic given every two months, is the first to target the antithrombin protein instead of missing clotting factors in the blood.
| 8 min read
Explore how single-dose gene therapy offers a potential long-term treatment for hemophilia, and discover the challenges contributing to its low adoption.
| 2 min read
On a quest to bring new a new hemophilia gene therapy to the clinic, one research team leapt over hurdle after hurdle to produce enough viral therapeutics to treat a large number of patients.
| 2 min read
Catalyst Biosciences gains FDA Fast Track designation for subcutaneous MarzAA for the treatment of Hemophilia
Page 1 of 1 - 4 Total Items
